U.S. physicians disagree with Germany’s determinations of the value of diabetes medicines

According to a recent study from Health Strategies Insights by EVERSANA, 89% of U.S. physicians disagree with Germany’s determinations of the clinical benefit of innovative diabetes medicines.

Learn more about our Market Access products & capabilities!

Contact us with your questions and data needs, and an expert will follow up shortly.

Download
“U.S. physicians disagree with Germany’s determinations of the value of diabetes medicines”
Downloaded 18 times – 98 KB
Author Team
no-image
Health Strategies Insights Team

Health Strategies Insights by EVERSANA gives you an advanced set of capabilities, frameworks, and methods. These are all derived from a robust stakeholder panel, providing critical answers to your specific payer marketing and market access questions. Learn More About Health Strategies Insights.